@TobyMMaher

Director of ILD @KeckMedUSC. @imperialNHLI Honorary Prof of Interstitial Lung Disease and #IPF doctor. Working to #cureIPF

 Los Angeles, CA
profiles.sc-ctsi.org/toby.maher
Joined March 2012
  • Tweets725
  • Following499
  • Followers3.3K
32Media
Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial Deupirfenidone slowed the rate of FVC decline compared with placebo in IPF doi.org/10.1093/ajrccm/aamag… @TobyMMaher @atscommunity
3
6
905
The first snRNASeq & spatial transcriptomic analysis of bronchoscopic cryobiopsies from patients with Early IPF & preserved pulmonary functions is out on @biorxivpreprint and message is Early IPF is IPF‼️ biorxiv.org/content/10.64898…
3
26
1
72
10,480
Feat: @TobyMMaher, Justin Oldham MD, and Marlies Wijsenbeek MD Moderaters: @CarlaRCopeland and Ayodeji Adegunsoye MD @ATS_Assemblies
1
3
331
Toby Maher retweeted
PeerView
@PeerView22 Oct 2025
Shoutout to @drcastelino, @tobymmaher, and Dr. Flaherty for leading an amazing discussion at #CHEST2025! Real-world takeaways for real-world care. 📺 Replay available here: bit.ly/FibrosingILDT Thanks to @Boehringer for their educational grant support #CME #MedEd
4
9
370
Toby Maher retweeted
PeerView
@PeerView21 Oct 2025
Watch Toby Maher, MD, MSc, PhD (@TobyMMaher), Flavia Castelino, MD (@drcastelino), and Kevin R. Flaherty, MD, MS discuss clearing the air on fibrosing ILDs at #CHEST2025 – to participate, visit: bit.ly/FibrosingILDT xitter.cf/i/broadcasts/1mrGmBbkW…
4
10
320
Toby Maher retweeted
PeerView
@PeerView14 Oct 2025
Join Toby Maher, MD, MSc, PhD (@tobymmaher), Flavia Castelino, MD (@drcastelino), and Kevin R. Flaherty, MD, MS, on 10/21 at 6:00 AM CDT during #CHEST2025 for a #fibrosingILD #MedEd event. 🔗 bit.ly/FibrosingILDT #pulmonology
3
9
365
Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade. Congratulations to all our patients & yes, even better drugs are on the way!! Great day for #CureIPF #ScienceMatters fda.gov/drugs/news-events-hu…
4
10
1
34
2,344
⚡ Up your #fibrosingILD game! Join @PeerView + the experts Drs. Toby Maher (@tobymmaher) & Castelino (@drcastelino) at #CHEST2025 (Oct 21 | 6 AM CDT) for a rapid-fire TownHall on antifibrotics, immunomodulators & emerging therapies. 🫁 👉 bit.ly/FibrosingILDT #MedEd
3
7
346
🚨 Stay ahead in #fibrosingILD care! Join @PeerView with Drs. Maher (@tobymmaher) & Castelino (@drcastelino) at #CHEST2025 on 10/21 at 6 AM CDT for a TownHall on diagnosis, management & emerging therapies. Register: bit.ly/FibrosingILDT #MedEd #pulmonology #ILD
5
6
369
Toby Maher retweeted
PeerView
@PeerView11 Sep 2025
"#FibrosingILD: Conversations on Timely Diagnosis and Antifibrotic Therapy” with Drs. Maher (@tobymmaher) & Castelino (@drcastelino). 10/21 at 6:00 AM CDT. bit.ly/FibrosingILDT #CHEST2025 #pulmonology
3
7
410
What do most clinicians miss about idiopathic pulmonary fibrosis? Find out in the latest episode, where @doctor_saranya speaks with @TobyMMaher about what defines Interstitial Lung Disease, how idiopathic pulmonary fibrosis fits into the picture and more: hubs.la/Q03G8R-W0
4
8
484
Fantastic news for all our patients with IPF who suffer with cough! An overall 43% reduction in cough counts, similar improvement in patient reported cough and benefits seen in 2 weeks. We look forward to the phase 3 study!
Trevi Therapeutics@TreviThera2 Jun 2025
We are pleased to share the positive topline results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough.   Join our conference call today, June 2nd, at 8:30 a.m. ET.  Read the press release: ow.ly/MCzh50W2spG $TRVI
12
2
44
2,275
When it rains it pours!! What an amazing #ATS2025 for #CurePF4ALL! Nerandomilast -> ⬇️FVC decline compared to placebo in Progressive Pulmonary Fibrosis patients on antifibrotics or untreated. 👏🏼 Drs Maher, Martinez & #FibroneerILD team!! nejm.org/doi/full/10.1056/NE…
1
19
78
6,794
Wow! What a day for #CureIPF & #ATS2025! First positive drug trial in 10 years in IPF!! Treatment with Nerandomilast -> ⬇️FVC decline compared to placebo in patients on antifibrotics or untreated. Kudos Drs Richeldi and Wijsenbeek and #FibroneerIPF team nejm.org/doi/full/10.1056/NE…
2
33
104
9,207
Great to see publication of the first positive phase 3 trial in patients with IPF. This represents an important step forward in the treatment of this terrible disease. #cureipf
NEJM
@NEJM18 May 2025
Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU @atscommunity
A bar chart showing the change from baseline in forced vital capacity at week 52 in the overall trial population

ALT A bar chart showing the change from baseline in forced vital capacity at week 52 in the overall trial population

2
14
47
2,884
A reminder to tune in to our session at #ATS2025 on cough in pulmonary fibrosis. Join @TobyMMaher to discuss how new technologies and patient-reported outcomes can address this gap in IPF research. Add to your calendar and join us! calendarlink.com/event/8aCAe #IPF #digitalhealth
1
3
284
#ArtificialIntelligence and the Diagnosis of #InterstitialLungDisease: Are We Ready for ChatMDT?! onlinelibrary.wiley.com/doi/… an Editorial by @TobyMMaher on recent research: onlinelibrary.wiley.com/doi/… Follow us on Bluesky: @respirology.bsky.social
1
6
11
870
Join Strados Labs and @TobyMMaher at #ATS2025 for an engaging session on the often-overlooked symptom of cough in pulmonary fibrosis and ways we can address the gap. May 19, 11:55 AM PST | Exhibitor Hall Innovation Hub #7 We look forward to seeing you there! #IPF
2
3
298
Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non-Responders in IPF? onlinelibrary.wiley.com/doi/… and Editorial by Toby Maher @tobymmaher on recent research: onlinelibrary.wiley.com/doi/… Follow us on Bluesky: @respirology.bsky.social
1
3
439
Fibrosis: cross-organ biology and pathways to development of innovative drugs nature.com/articles/s41573-0… This new Review highlights core pathways active in fibrotic conditions across organs, and proposes strategies to improve the translation of potential antifibrotic drugs
54
4
193
15,476
Load more